Literature DB >> 9179087

Effect of angiotensin-converting enzyme inhibitor therapy in mitral regurgitation with normal left ventricular function.

F Marcotte1, G N Honos, A D Walling, D Beauvais, M J Blais, C Daoust, A Lisbona, J L McCans.   

Abstract

Mitral regurgitation (MR) is a common, frequently asymptomatic valvulopathy that can ultimately lead to left ventricular failure. With the objective of forestalling MR progression, a prospective, placebo controlled, double-blind study was conducted. It measured the effectiveness of lisinopril, an angiotensin-converting enzyme inhibitor, in reducing the echocardiographic signs of MR severity over a one-year period. Severe coronary disease was excluded by stress echocardiography. Treatment effectiveness was estimated to be proportional to the reduction in MR fraction and cardiac chamber dimensions, compared with baseline, according to intention-to-treat analysis. A final patient population of 23 asymptomatic adults aged 53.3 +/- 2.4 years (mean +/- SEM), with moderate, organic MR and normal left ventricular function was selected from the echocardiographic database. All baseline patient characteristics were comparable in the two treatment groups, including the MR fraction (55 +/- 3%). Twelve patients received lisinopril (18 +/- 1 mg) and 11 received placebo. After one year of treatment, a statistically significant difference in the MR fraction was observed between the two groups. For the lisinopril group the MR fraction dropped by 6.4 +/- 3.5% and for the placebo group it increased by 3.7 +/- 3.2% versus baseline (P < 0.05). No differences in left atrial or ventricular dimensions were observed. The study drug was stopped in four patients after one patient presented with rapid atrial fibrillation and angina while three patients were intolerant to lisinopril. Only one patient receiving placebo was taken off therapy. In conclusion, treatment with lisinopril indicates some reduction in the severity of chronic moderate MR in asymptomatic patients with normal left ventricular function. This approach appears to be safe, but side effects are not uncommon, warranting regular follow-up.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9179087

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  5 in total

1.  Mitral valve repair in the treatment of mitral regurgitation.

Authors:  Blase A Carabello
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-12

Review 2.  The renin-angiotensin system in mitral regurgitation: a typical example of tissue activation.

Authors:  Louis J Dell'Italia
Journal:  Curr Cardiol Rep       Date:  2002-03       Impact factor: 2.931

Review 3.  Drug Therapy for Heart Valve Diseases.

Authors:  Jeffrey S Borer; Abhishek Sharma
Journal:  Circulation       Date:  2015-09-15       Impact factor: 29.690

Review 4.  The management of functional mitral regurgitation.

Authors:  Blase A Carabello
Journal:  Curr Cardiol Rep       Date:  2007-04       Impact factor: 2.931

5.  Impact of chronic lisinopril therapy on left atrial volume versus dimension in chronic organic mitral regurgitation.

Authors:  Graham C Wong; Francois Marcotte; Lawrence G Rudski
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.